Loading
Co-developed imatinib's successor dasatinib and the prostate drug enzalutamide, and explained how cancers resist targeted drugs.
Physician-scientist who characterised BCR-ABL resistance mutations, co-developed dasatinib, and with Michael Jung co-invented enzalutamide and apalutamide. His laboratory studies androgen receptor signalling and lineage plasticity in castration-resistant prostate cancer. Lasker Award 2009, Breakthrough Prize 2013.
A mechanism for the most feared form of treatment resistance in prostate cancer, and the reason combined TP53 and RB1 loss is worth knowing about before a man starts an androgen receptor drug rather than after his biopsy comes back neuroendocrine. Reversibility in the laboratory is also an argument that the switch is a target and not just a prognosis.
The genomic definition of advanced prostate cancer, and the evidence that made molecular testing standard in it. The 19.3 percent DNA repair figure is the direct ancestor of PROfound, TRITON3, PROpel and TALAPRO-2, and the 8 percent germline figure is why a tumour result in this disease has implications for a man's relatives.
The origin of the idea that a prostate tumour's copy-number pattern carries prognostic information the pathologist's grade does not. That idea became Decipher and the other genomic classifiers, which are now used in some systems to decide whether a man needs radiotherapy after surgery.
The design specification for the second-generation antiandrogens. A drug for castration-resistant prostate cancer has to stay an antagonist when the receptor is abundant, which is what enzalutamide, apalutamide and darolutamide were engineered to do and what bicalutamide fails to do.
Shares Stand Up To Cancer, Enzalutamide, Androgen receptor, Memorial Sloan Kettering Cancer Center.
Shares Prostate Cancer Foundation, Stand Up To Cancer, Enzalutamide, Androgen receptor.
Shares Michael Milken, Prostate Cancer Foundation, Memorial Sloan Kettering Cancer Center, Prostate cancer.
Shares Brian Druker, BCR::ABL1 (Philadelphia chromosome), Androgen receptor, Prostate cancer.
Shares Apalutamide, Enzalutamide, Prostate cancer.
Shares Apalutamide, Enzalutamide, Prostate cancer.
Shares Molecular determinants of resistance to antiandrogen therapy, Enzalutamide, Androgen receptor, Prostate cancer.
Shares Molecular determinants of resistance to antiandrogen therapy, SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer, Enzalutamide, Androgen receptor.